ArticleAntimicrobial agents and chemotherapy2000
Pentamidine inhibition of group I intron splicing in Candida albicans correlates with growth inhibition.
Article in Antimicrobial agents and chemotherapy, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 60 citations in OpenAlex.
- Uncovering the role of mitochondrial genome in pathogenicity and drug resistance in pathogenic fungi.Frontiers in cellular and infection microbiology · 2025Review
- Group I introns: Structure, splicing and their applications in medical mycology.Genetics and molecular biology · 2024Article
- Distribution and Polymorphisms of Group I Introns in Mitochondrial Genes fromJournal of fungi (Basel, Switzerland) · 2023Article
- Repurposing non-antifungal drugs auranofin and pentamidine in combination as fungistatic antifungal agents againstFrontiers in cellular and infection microbiology · 2022Article
- Repurposing of Ribavirin as an Adjunct Therapy against InvasiveAntimicrobial agents and chemotherapy · 2019Article
- Mitigating RNA Toxicity in Myotonic Dystrophy using Small Molecules.International journal of molecular sciences · 2019Review
- Insights into the development of chemical probes for RNA.Nucleic acids research · 2018Article
- A Molecular Window into the Biology and Epidemiology of Pneumocystis spp.Clinical microbiology reviews · 2018Review
- Drugging tRNA aminoacylation.RNA biology · 2018Review
- Polymorphism in Mitochondrial Group I Introns amongFrontiers in microbiology · 2018Article
- Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance.Nature microbiology · 2017Article
- Evolution and Application of Inteins inFrontiers in microbiology · 2016Review
- T-2307 causes collapse of mitochondrial membrane potential in yeast.Antimicrobial agents and chemotherapy · 2012Article
- Chemical correction of pre-mRNA splicing defects associated with sequestration of muscleblind-like 1 protein by expanded r(CAG)-containing transcripts.ACS chemical biology · 2012Article
- Identifying the preferred RNA motifs and chemotypes that interact by probing millions of combinations.Nature communications · 2012Article
- Pentamidine inhibits Coxiella burnetii growth and 23S rRNA intron splicing in vitro.International journal of antimicrobial agents · 2010Article
- Slow formation of a pseudoknot structure is rate limiting in the productive co-transcriptional folding of the self-splicing Candida intron.RNA (New York, N.Y.) · 2009Article
- Small molecule microarrays of RNA-focused peptoids help identify inhibitors of a pathogenic group I intron.ACS chemical biology · 2009Article
- In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.Antimicrobial agents and chemotherapy · 2008Article
- Pentamidine binds to tRNA through non-specific hydrophobic interactions and inhibits aminoacylation and translation.Nucleic acids research · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
We previously demonstrated that pentamidine, which has been clinically used against Pneumocystis carinii, inhibits in vitro a group I intron ribozyme from that organism. Another fungal pathogen, Candida albicans, also harbors a group I intron ribozyme (Ca.LSU) in the essential rRNA genes in almost half of the clinical isolates analyzed. To determine whether pentamidine inhibits Ca.LSU in vitro and in cells, phylogenetically closely related intron-containing (4-1) and intronless (62-1) strains were studied. Splicing in vitro of the Ca.LSU group I intron ribozyme was completely inhibited by pentamidine at 200 microM. On rich glucose medium, the intron-containing strain was more sensitive to growth inhibition by pentamidine than was the intronless strain, as measured by disk or broth microdilution assays. On rich glycerol medium, they were equally susceptible to pentamidine. At pentamidine levels selectively inhibiting the intron-containing strain (1 microM) in glucose liquid cultures, inhibition of splicing and rRNA maturation was detected by quantitative reverse transcription-PCR within 1 min with a 10- to 15-fold accumulation of precursor rRNA. No comparable effect was seen in the intronless strain. These results correlate the cellular splicing inhibition of Ca.LSU with the growth inhibition of strain 4-1 harboring Ca.LSU. Broth microdilution assays of 13 Candida strains showed that intron-containing strains were generally more susceptible to pentamidine than the intronless strains. Our data suggest that ribozymes found in pathogenic microorganisms but absent in mammals may be targets for antimicrobial therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.